[EN] DUAL ACTING FKBP12 AND FKBP52 INHIBITORS<br/>[FR] INHIBITEURS DE FKBP12 ET DE FKBP52 À DOUBLE ACTION
申请人:PLEX PHARMACEUTICALS INC
公开号:WO2019040463A1
公开(公告)日:2019-02-28
Provided are novel compounds of Formulas (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful as dual FKBP12/FKABP inhibitors. Also provided are pharmaceutical compositions comprising the novel compounds of Formulas (I) and (II) and their use in treating Parkinson's disease.
Provided are novel compounds of Formulas (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful as dual FKBP12/FKABP inhibitors. Also provided are pharmaceutical compositions comprising the novel compounds of Formulas (I) and (II) and their use in treating Parkinson's disease.
Diazo compounds of the heterocyclic series. 4. Some peculiarities of the diazo coupling of benzimidazole-2-diazonium salts with phenols and their ethers
作者:S. N. Kolodyazhnaya、L. N. Divaeva、R. A. Sogomonova、A. M. Simonov
DOI:10.1007/bf00487430
日期:1990.5
Different pathway of nucleophilic substitution in 2-methoxynaphthylazo- and 2-methoxyphenyl-azobenzimidazole
作者:S. N. Kolodyazhnaya、L. N. Divaeva、O. V. Drebentsova、A. M. Simonov